BNCT induced immunomodulatory effects contribute to mammary tumor inhibition.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Publication Year:
      2019
    • Subject Terms:
    • Author-Supplied Keywords:
      Anatomy
      Animal cells
      Biology and life sciences
      Blood
      Blood cells
      Body fluids
      Boron
      Cancer treatment
      Cell biology
      Cellular structures and organelles
      Cellular types
      Chemical elements
      Chemistry
      Clinical medicine
      Clinical oncology
      Diagnostic medicine
      Immune cells
      Immunology
      Liposomes
      Macrophages
      Medicine and health sciences
      Necrosis
      Nuclear physics
      Nucleons
      Oncology
      Pathology and laboratory medicine
      Physical sciences
      Physics
      Physiology
      Radiation therapy
      Research Article
      Signs and symptoms
      Vesicles
      White blood cells
    • Abstract:
      In the United States, breast cancer is one of the most common and the second leading cause of cancer-related death in women. Treatment modalities for mammary tumor are surgical removal of the tumor tissue followed by either chemotherapy or radiotherapy or both. Radiation therapy is a whole body irradiation regimen that suppresses the immune system leaving hosts susceptible to infection or secondary tumors. Boron neutron capture therapy (BNCT) in that regard is more selective, the cells that are mostly affected are those that are loaded with 109 or more 10B atoms. Previously, we have described that liposomal encapsulation of boron-rich compounds such as TAC and MAC deliver a high payload to the tumor tissue when injected intravenously. Here we report that liposome-mediated boron delivery to the tumor is inversely proportional to the size of the murine mammary (EMT-6) tumors. The plausible reason for the inverse ratio of boron and EMT-6 tumor size is the necrosis in these tumors, which is more prominent in the large tumors. The large tumors also have receding blood vessels contributing further to poor boron delivery to these tumors. We next report that the presence of boron in blood is essential for the effects of BNCT on EMT-6 tumor inhibition as direct injection of boron-rich liposomes did not provide any added advantage in inhibition of EMT-6 tumor in BALB/c mice following irradiation despite having a significantly higher amount of boron in the tumor tissue. BNCT reaction in PBMCs resulted in the modification of these cells to anti-tumor phenotype. In this study, we report the immunomodulatory effects of BNCT when boron-rich compounds are delivered systemically. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of PLoS ONE is the property of Public Library of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • ISSN:
      19326203
    • Accession Number:
      138403869
  • Citations
    • ABNT:
      KHAN, A. A. et al. BNCT induced immunomodulatory effects contribute to mammary tumor inhibition. PLoS ONE, [s. l.], v. 14, n. 9, p. 1, 2019. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=138403869. Acesso em: 4 jun. 2020.
    • AMA:
      Khan AA, Maitz C, Quanyu C, Hawthorne F. BNCT induced immunomodulatory effects contribute to mammary tumor inhibition. PLoS ONE. 2019;14(9):1. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=138403869. Accessed June 4, 2020.
    • APA:
      Khan, A. A., Maitz, C., Quanyu, C., & Hawthorne, F. (2019). BNCT induced immunomodulatory effects contribute to mammary tumor inhibition. PLoS ONE, 14(9), 1.
    • Chicago/Turabian: Author-Date:
      Khan, Aslam Ali, Charlie Maitz, Cai Quanyu, and Fred Hawthorne. 2019. “BNCT Induced Immunomodulatory Effects Contribute to Mammary Tumor Inhibition.” PLoS ONE 14 (9): 1. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=138403869.
    • Harvard:
      Khan, A. A. et al. (2019) ‘BNCT induced immunomodulatory effects contribute to mammary tumor inhibition’, PLoS ONE, 14(9), p. 1. Available at: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=138403869 (Accessed: 4 June 2020).
    • Harvard: Australian:
      Khan, AA, Maitz, C, Quanyu, C & Hawthorne, F 2019, ‘BNCT induced immunomodulatory effects contribute to mammary tumor inhibition’, PLoS ONE, vol. 14, no. 9, p. 1, viewed 4 June 2020, .
    • MLA:
      Khan, Aslam Ali, et al. “BNCT Induced Immunomodulatory Effects Contribute to Mammary Tumor Inhibition.” PLoS ONE, vol. 14, no. 9, Sept. 2019, p. 1. EBSCOhost, search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=138403869.
    • Chicago/Turabian: Humanities:
      Khan, Aslam Ali, Charlie Maitz, Cai Quanyu, and Fred Hawthorne. “BNCT Induced Immunomodulatory Effects Contribute to Mammary Tumor Inhibition.” PLoS ONE 14, no. 9 (September 2, 2019): 1. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=138403869.
    • Vancouver/ICMJE:
      Khan AA, Maitz C, Quanyu C, Hawthorne F. BNCT induced immunomodulatory effects contribute to mammary tumor inhibition. PLoS ONE [Internet]. 2019 Sep 2 [cited 2020 Jun 4];14(9):1. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=138403869